Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis
Three adults with symptomatic mesenteric panniculitis were treated with 4.5mg of LDN nightly for 12 weeks. Clinical response was defined as diminution of symptoms at 4 and 8 weeks. A biochemical response was reduction in the ESR or CRP at 4 weeks. All had decrease in MPSAS at 4 weeks, 2 of 3 had decrease at 8 weeks
LDN was safe and well tolerated.